Nimotuzumab significantly enhances chemosensitivity of PC9 human lung adenocarcinoma cells to paclitaxel in vitro

Chinese Journal of Lung Cancer

Volumn 18, Issue 2, 2015, Pages 98-103

  Xiao, Yu ^a   Cao, Bao Shan ^a   Liang, Li ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

Lung neoplasms; Nimotuzumab; Paclitaxel; PC9

Indexed keywords

CISPLATIN; GEMCITABINE; NAVELBINE; NIMOTUZUMAB; PACLITAXEL; PEMETREXED; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHEMOSENSITIVITY; DNA DETERMINATION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; LUNG ADENOCARCINOMA; NICK END LABELING; WST-1 ASSAY; ADENOCARCINOMA; CELL CYCLE; DRUG EFFECTS; DRUG POTENTIATION; LUNG NEOPLASMS; PATHOPHYSIOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; HUMANS; LUNG NEOPLASMS; PACLITAXEL;

EID: 84922743699     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2015.02.10     Document Type: Article

References (26)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin, 2013, 63(1): 11-30.
2. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol, 2007, 2(8): 706-714.
3. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 2010, 362(25): 2380-2388.
4. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 2009, 361(10): 947-957.
5. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol, 2010, 11(2): 121-128.
6. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol, 2012, 13(3): 239-246.
7. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol, 2011, 12(8): 735-742.
8. Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014, 15(2): 213-222.
9. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med, 2013, 368(25): 2385-2394.
10. Song H, Pan B, Yi J, et al. Featured article: autophagic activation with nimotuzumab enhanced chemosensitivity and radiosensitivity of esophageal squamous cell carcinoma. Exp Biol Med (Maywood), 2014, 239(5): 529-541.
11. Qu YY, Hu SL, Xu XY, et al. Nimotuzumab enhances the radiosensitivity of cancer cells in vitro by inhibiting radiation-induced DNA damage repair. PLoS One, 2013, 8(8): e70727.
12. Solomon MT, Miranda N, Jorrin E, et al. Nimotuzumab in combination with radiotherapy in high grade glioma patients: a single institution experience. Cancer Biol Ther, 2014, 15(5): 504-509.
13. 2/M phase. Cell Biol Int, 2015, 39(2): 146-151.
14. Song HZ, Yi J, Chen J, et al. Nimotuzumab increases chemosensitivity of human lung adenocarcinoma cell lines to docetaxel. Oncol Res, 2012, 20(1): 39-47.
15. Su D, Jiao SC, Wang LJ, et al. Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer. Tumour Biol, 2014, 35(3): 2313-2318.
16. Jiang YQ, Zhou ZX, Ji YL. Suppression of EGFR-STAT3 signaling inhibits tumorigenesis in a lung cancer cell line. Int J Clin Exp Med, 2014, 7(8): 2096-2099.
17. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet, 2009, 373(9674): 1525-1531.
18. Fischer JR, Griesinger F, Fink T, et al. Docetaxel- carboplat in chemotherapy combined with cetux imab in patients with locally advanced or metastatic non small-cell lung cancer (NSCLC)-results of the nonrandomised phase II study TaxErb. Lung Cancer, 2012, 75(3): 348-352.
19. Kim ES, Neubauer M, Cohn A, et al. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial. Lancet Oncol, 2013, 14(13): 1326-1336.
20. Boland W, Bebb G. The emerging role of nimotuzumab in the treatment of non-small cell lung cancer. Biologics, 2010, 4: 289-298.
21. Liang J, E M, Wu G, et al. Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a phase II clinical trial. Oncol Targets Ther, 2013, 6: 1589-1596.
22. Rodriguez MO, Rivero TC, del Castillo Bahi R, et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther, 2010, 9(5): 343-349.
23. Reddy BK, Lokesh V, Vidyasagar MS, et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients. Oral Oncol, 2014, 50(5): 498-505.
24. Basavaraj C, Sierra P, Shivu J, et al. Nimotuzumab with chemoradiation confers a survival advantage in treatment-naive head and neck tumors over expressing EGFR. Cancer Biol Ther, 2010, 10(7): 673-681.
25. Wang Y, Pan L, Sheng XF, et al. Nimotuzumab, a humanized monoclonal antibody specific for the EGFR, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: First results in Chinese patients. Asia Pac J Clin Oncol, 2014. [Epub ahead of print]
26. Babu KG, Prabhash K, Vaid AK, et al. Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small-cell lung cancer: a multicenter, randomized, open-label phase II study. Oncol Targets Ther, 2014, 7: 1051-1060.